The estimated pooled HR for all studies suggested that the risk of death was not associated with intraepithelial FoxP3+ TILs in ovarian cancer patients (Figure 4A; HR, 0.98; 95%CI, 0.80-1.19; PHR=0.83; I2=71.2%; random effects model). Here, FOXP3 is linked to ovarian cancer.